Supplementary Appendix A

List of co-authors from Thromkid-Plus Studiengruppe (GTH) 2016 (October) and participants of the laboratory external quality assessment: Oliver Andres, University Children's Hospital Würzburg, Würzburg, Germany; Matthias Ballmaier, Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; Frauke Bergmann, MVZ wagner-stibbe, amedes Gruppe, Hannover, Germany; Peter Bugert, Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany; Holger Cario, Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany; Christof Dame, Department of Neonatology, Charité, Berlin, Germany; Johanna Gebhart, Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; Susan Halimeh, Gerinnungszentrum Rhein-Ruhr (GZRR), Duisburg, Germany; Susanne Holzhauer, Department of Pediatric Haematology/Oncology, Charité, Berlin, Germany; Guenther Kappert, Gerinnungszentrum Rhein-Ruhr (GZRR), Duisburg, Germany; Beate Kehrel, Experimental and Clinical Haemostasis, University Hospital Muenster, Muenster, Germany; Michael Krause, MVZ Labor Dr. Reising-Ackermann und Kollegen, Leipzig, Germany; Oliver Mayer, Institute of Transfusion Medicine, Charité - Universitätsmedizin Berlin, Germany; Wolfgang Miesbach, Medical Clinic II, Institute of Transfusion Medicine, Goethe University, Frankfurt, Germany; Martin Olifferi, LMU Munich, University Hospital, Dr. von Hauner Children's Hospital, Department of Pediatric Hemostasis and Thrombosis, Munich, Germany; Florian Prueller, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria; Christian Reif, Department of Pediatrics I, Medical University Innsbruck, Innsbruck, Austria; Ulrich Sachs, Institut für Klinische Immunologie und Transfusionsmedizin, Universitätsklinikum Gießen, Gießen, Germany; Markus Schmugge, Department of Hematology, University Children's Hospital Zurich, Zurich, Switzerland; Harald Schulze, Institute of Experimental Biomedicine I, University Hospital Würzburg, Germany; Annelie Siegemund, Clinical Hemostaseology, Medical ICU and Department of Pneumology, University of Leipzig, Germany; Andrea Gerhardt, BGU Blutgerinnung Ulm, Ulm, Germany; Clemens Stockklausner, Klinik für Kinder- und Jugendmedizin, Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany; Gabriele Strauß, Pädiatrische Hämatologie/Onkologie, Helios Klinikum Berlin Buch, Berlin, Germany; Oliver Triebel, Children's Carl Gustav Carus Dresden University Hospital, Dresden, Germany; Ilona Wieland, Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; Werner Streif, Department of Pediatrics I, Medical University Innsbruck, Innsbruck, Austria.

Supplementary Fig. S1 One of 15 laboratories reported their results and all shipments were received within 24 hours without any visible damage or leakage. One laboratory was excluded because of technical problems with shipment of agonists. Attendees received samples with overnight express, but not for every laboratory it was possible to measure the agonist on the same day. Thirteen of 15 laboratories documented their time of performance (mean: 5.3 days, range: 01–10 day(s)).
Supplementary Fig. S2 Representative and non-representative light transmission aggregometry (LTA) curves obtained within the inter-laboratory trial study. (A) Representative LTA curves sent by one participating laboratory with an APACT aggregometer using the shipped set 1 agonists. (B) Representative LTA curves sent by one participating laboratory with a PAP4 aggregometer using the shipped set 1 agonists. (C) Non-representative LTA curves sent by one participating laboratory with an APACT aggregometer using the shipped set 1 agonists. Here, the laboratory added the agonists after 300 seconds of stirring the platelet-rich plasma (PRP) at 37°C in the aggregometer.